Blood test could spare kidney cancer patients from unneeded drug therapy
NCT ID NCT06005818
Summary
This study is testing a personalized approach to treatment after surgery for kidney cancer. It uses a special blood test to look for tiny traces of leftover cancer. Patients who test negative for this 'molecular residual disease' will skip standard follow-up drug treatment, while those who test positive will receive it. The goal is to see if this strategy is safe and effective at preventing the cancer from returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35233, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.